Antihypertensive Therapy in Advanced Chronic Kidney Disease

Introduction to Antihypertensive Therapy

The American Journal of Kidney Diseases recommends ACE inhibitors or ARBs as first-line antihypertensive agents for patients with CKD stage 5 and GFR <10 mL/min, with a target blood pressure <130/80 mmHg, though evidence is limited in this advanced stage and careful monitoring for hyperkalemia and acute kidney injury is essential 1

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest a target BP <130/80 mmHg is reasonable for CKD stages 4-5 not on dialysis, though this recommendation is based on extrapolation from earlier CKD stages rather than direct trial evidence 1
The KDIGO 2019 commentary acknowledges insufficient high-quality data for specific BP targets in CKD stages 4 and 5, as most trials including SPRINT excluded patients with advanced CKD (eGFR <20 mL/min) 1
More intensive BP lowering in advanced CKD may accelerate the need for kidney replacement therapy in some patients, particularly older individuals with low diastolic BP from arterial stiffness 1
The risk of acute kidney injury is substantially higher in CKD stages 4-5 compared to earlier stages, requiring cautious BP reduction 1

The American College of Cardiology recommends ACE inhibitors or ARBs as first-line therapy when moderate-to-severe albuminuria is present, even in advanced CKD 1, 2
These agents provide renoprotection beyond BP lowering through reduction of intraglomerular pressure and proteinuria 3
ARBs may cause less hyperkalemia than ACE inhibitors in patients with eGFR <60 mL/min, though both require close monitoring 3

Consider reducing the ACE inhibitor/ARB dose or discontinuing if creatinine rises >30% from baseline or if hyperkalemia develops 3
Diuretic-induced intravascular volume depletion is the most common avoidable reason for creatinine elevation with RAS inhibitors 3
The initial decline in GFR after starting ACE inhibitors/ARBs is attributable to disordered autoregulation and does not necessarily indicate treatment failure 3
Check serum potassium and creatinine within 5-7 days after initiating or adjusting RAS inhibitor doses in advanced CKD 1

Loop diuretics are typically required in CKD stage 5 for volume control, as thiazide diuretics lose efficacy at GFR <30 mL/min 1
Volume control with loop diuretics may be needed in patients with signs of volume overload and in those with nephrotic-range proteinuria 1
Long-acting dihydropyridine calcium channel blockers are reasonable second-line agents and can be used at any level of kidney function 1
CCBs do not require dose adjustment based on renal function and carry lower risk of hyperkalemia compared to RAS inhibitors 1

Newer potassium binders (patiromer, sodium zirconium cyclosilicate) can enable continuation of RAS inhibitors in patients who develop hyperkalemia 4
If potassium >5.5 mEq/L, halve the dose of RAS inhibitors and closely monitor; if >6.0 mEq/L, discontinue RAS inhibitors temporarily 4
Avoid potassium-sparing diuretics (spironolactone, amiloride, triamterene) when GFR <30 mL/min due to prohibitive hyperkalemia risk 1

Do not discontinue ACE inhibitors/ARBs prematurely when creatinine rises <30%, as this initial rise is expected and does not indicate harm 3
Avoid relying on serum creatinine alone; always calculate eGFR using validated equations (MDRD or CKD-EPI) that account for age, sex, and body size 5
Do not prescribe thiazide diuretics as monotherapy when GFR <30 mL/min, as they are ineffective at this level of renal function 1
Avoid NSAIDs entirely, as they cause sodium retention, worsen renal function, and increase hyperkalemia risk with RAS inhibitors 4
Do not combine ACE inhibitors with ARBs routinely, as this increases adverse events without clear benefit in advanced CKD 1